FindTrial
Sign In

IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center

Conditions

EpendymomaGlioblastomaMalignant Brain NeoplasmMedulloblastomaRecurrent Malignant Brain NeoplasmRecurrent Metastatic Malignant Neoplasm in the LeptomeningesRefractory Malignant Brain Neoplasm

Phase 1

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
RecruitingNCT04510051
City of Hope Medical CenterMalignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
Start: 2020-12-04End: 2027-02-24Target: 18Updated: 2026-03-05
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
Active, not recruitingNCT04661384
City of Hope Medical CenterEpendymoma, Glioblastoma, Medulloblastoma +1
Start: 2021-03-05End: 2027-01-12Updated: 2026-03-05

Related Papers

CTIM-21. PRELIMINARY PERFUSION IMAGING RESULTS FROM PHASE 1 STUDY OF IL13RΑ2-TARGETED CAR-T CELLS FOR LEPTOMENINGEAL BRAIN TUMORS
Neuro-Oncology2025-11-01
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
2024-03-07187 citations